Mode
Text Size
Log in / Sign up
N/A Completed N=42

A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.

Source: ClinicalTrials.gov NCT00976950 ↗
Enrolled (actual)
42
Serious AEs
2.4%
Results posted
Aug 2012
Primary outcomePrimary: Number of Patients Reporting Adverse Events (AE) — 6; 1; 4; 1 Participants

Summary

The aim of this trial is to evaluate the safety and virological and immunological efficacy of Aptivus in treatment-experienced patients with advanced HIV-1 infection who had developed resistance to more than one protease inhibitor.

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Patients Reporting Adverse Events (AE)
6; 1; 4; 1; 2 —
SECONDARY
Virologic Response
0; 4; 38 —
SECONDARY
Change in CD4+ Cell Count From Baseline at Week 48
85.8 —

Eligibility Criteria

Inclusion criteria

  • HIV-1 infected patients who are treatment experienced and infected with HIV-1 strains resistant to more than one protease inhibitor and no other therapeutic options.
  • The inclusion criteria follow the same criteria which are describe in the newest SPC

Exclusion criteria

The exclusion criteria follow the same criteria which are describe in the newest SPC

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00976950). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search